2 weeks Ago By ABMN Staff
Sei Investments Co. increased its position in shares of Corcept Therapeutics Incorporated ( NASDAQ:CORT – Free Report ) by 120.0% in the fourth quarter, Holdings Channel reports.
The institutional investor owned 99,943 shares of the biotechnology company’s stock after buying an additional 54,521 shares during the period. Sei Investments Co.’s holdings in Corcept Therapeutics were worth $5,036,000 as of its most recent SEC filing.
A number of other hedge funds and other institutional investors have also bought and sold shares of the company. Kestra Investment Management LLC bought a new position in shares of Corcept Therapeutics during the 4th quarter worth approximately $27,000. USA Financial Formulas acquired a new position in Corcept Therapeutics during the fourth quarter worth $54,000.
Newbridge Financial Services Group Inc. bought a new position in Corcept Therapeutics in the fourth quarter valued at $58,000. Principal Securities Inc.
increased its stake in Corcept Therapeutics by 63.6% in the 4th quarter. Principal Securities Inc.
now owns 1,243 shares of the biotechnology company’s stock valued at $63,000 after buying an additional 483 shares during the last quarter. Finally, Harvest Fund Management Co. Ltd bought a new stake in Corcept Therapeutics during the 4th quarter worth about $69,000.
Institutional investors and hedge funds own 93.61% of the company’s stock. Corcept Therapeutics Trading Down 19.
5 % Shares of Corcept Therapeutics stock opened at $91.93 on Wednesday. The company has a debt-to-equity ratio of 0.
01, a current ratio of 3.70 and a quick ratio of 3.64.
The business has a fifty day simple moving average of $63.69 and a two-hundred day simple moving average of $55.67.
Corcept Therapeutics Incorporated has a 1 year low of $20.84 and a 1 year high of $117.33.
The company has a market capitalization of $9.70 billion, a price-to-earnings ratio of 72.96 and a beta of 0.
61. Insider Transactions at Corcept Therapeutics In other Corcept Therapeutics news, insider Sean Maduck sold 20,000 shares of Corcept Therapeutics stock in a transaction dated Thursday, January 2nd. The shares were sold at an average price of $50.
39, for a total value of $1,007,800.00. Following the completion of the sale, the insider now owns 85,318 shares in the company, valued at $4,299,174.
02. The trade was a 18.99 % decrease in their position.
The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website . Also, insider Joseph Douglas Lyon sold 421 shares of the business’s stock in a transaction dated Monday, March 24th. The shares were sold at an average price of $60.
58, for a total transaction of $25,504.18. Following the completion of the sale, the insider now directly owns 9,009 shares of the company’s stock, valued at $545,765.
22. This represents a 4.46 % decrease in their position.
The disclosure for this sale can be found here . Insiders sold a total of 48,022 shares of company stock worth $2,703,257 over the last quarter. Company insiders own 20.
50% of the company’s stock. Analyst Upgrades and Downgrades Several equities analysts have recently weighed in on CORT shares. Truist Financial raised their price objective on Corcept Therapeutics from $76.
00 to $150.00 and gave the company a “buy” rating in a report on Monday. StockNews.
com lowered Corcept Therapeutics from a “buy” rating to a “hold” rating in a research report on Friday, February 28th. Canaccord Genuity Group increased their price objective on Corcept Therapeutics from $130.00 to $142.
00 and gave the company a “buy” rating in a report on Tuesday. Piper Sandler boosted their target price on shares of Corcept Therapeutics from $67.00 to $78.
00 and gave the stock an “overweight” rating in a report on Thursday, February 27th. Finally, HC Wainwright increased their price target on shares of Corcept Therapeutics from $115.00 to $150.
00 and gave the company a “buy” rating in a research note on Monday. One investment analyst has rated the stock with a hold rating and five have issued a buy rating to the stock. According to data from MarketBeat.
com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $130.00. View Our Latest Stock Analysis on Corcept Therapeutics Corcept Therapeutics Company Profile ( Free Report ) Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States.
It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. Further Reading Want to see what other hedge funds are holding CORT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Corcept Therapeutics Incorporated ( NASDAQ:CORT – Free Report ).
Receive News & Ratings for Corcept Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corcept Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter ..
